Prostate cancer antigen 3 (nonprotein coding), formerly called differential display code 3 (DDC3), is expressed in prostate cells its overexpression serving as a biomarker for prostate cancer to complement the commonly used serum prostate-specific antigen (PSA). The combination of PCA3 together with other methods of detecting prostate cancer such as serum PSA, DRE, and TRUS biopsy represented an important advance in the early detection of this disease (see “Prostate Cancer Diagnosis”).
Prostate cancer is a tumour in which a biomarker, prostate-specific antigen (PSA), is employed to assist in diagnosis. However, an elevated PSA per se is not a specific enough test for prostate cancer but rather an indicator of its possibility, with histological confirmation usually via transrectal ultrasound (TRUS)-guided biopsy, required.
What has been lacking for prostate cancer is a biomarker of appropriate robustness for detection of the disease and for categorizing...
KeywordsProstate Cancer Benign Prostate Hyperplasia Detect Prostate Cancer Normal Prostate Tissue Prostate Cancer Antigen
- Machida T, Fujita T, Ooo ML, Ohira M, Isogai E, Mihara M, Hirato J, Tomotsune D, Hirata T, Fujimori M, Adachi W, Nakagawara A (2006) Increased expression of proapoptotic BMCC1, a novel gene with the BN1P2 and Cdc42GAP homology (BCH) domain, is associated with favourable prognosis in human neuroblastomas. Oncogene 25:1931–1942CrossRefPubMedGoogle Scholar
- Tomlins SA, Aubin SM, Siddiqui J et al (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3(94):94ra72. doi: 10.1126/scitranslmed.3001970Google Scholar